PGIM Jennison International Opportunities Fund
Schedule of Investments as of July 31, 2020 (unaudited)
Description | Shares | Value | |||
Long-Term Investments 98.4% | |||||
Common Stocks 94.1% | |||||
Argentina 5.0% | |||||
MercadoLibre, Inc.* | 79,296 | $89,177,867 | |||
Australia 1.5% | |||||
Cochlear Ltd. | 199,289 | 27,088,199 | |||
Canada 6.3% | |||||
Shopify, Inc. (Class A Stock)* | 109,261 | 111,883,264 | |||
China 17.0% | |||||
Alibaba Group Holding Ltd., ADR* | 295,274 | 74,119,679 | |||
Jiangsu Hengrui Medicine Co. Ltd. (Class A Stock) | 2,595,458 | 35,049,666 | |||
Kweichow Moutai Co. Ltd. (Class A Stock) | 92,095 | 22,075,316 | |||
Meituan Dianping (Class B Stock)* | 2,458,410 | 60,776,598 | |||
Tencent Holdings Ltd. | 1,079,836 | 73,707,306 | |||
Wuxi Biologics Cayman, Inc., 144A* | 1,869,084 | 38,615,274 | |||
304,343,839 | |||||
Denmark 2.2% | |||||
Novo Nordisk A/S (Class B Stock) | 597,725 | 39,349,202 | |||
France 14.3% | |||||
Dassault Systemes SE | 248,731 | 44,991,875 | |||
Kering SA | 45,858 | 26,312,101 | |||
L’Oreal SA | 173,364 | 57,559,068 | |||
LVMH Moet Hennessy Louis Vuitton SE | 140,886 | 61,097,018 | |||
Pernod Ricard SA | 224,026 | 38,427,445 | |||
Remy Cointreau SA(a) | 174,336 | 28,045,331 | |||
256,432,838 | |||||
Israel 3.8% | |||||
Nice Ltd., ADR* | 166,066 | 34,083,386 | |||
Wix.com Ltd.*(a) | 119,058 | 34,583,968 | |||
68,667,354 | |||||
Italy 4.8% | |||||
Brunello Cucinelli SpA* | 960,835 | 28,157,135 | |||
Ferrari NV | 323,494 | 58,284,096 | |||
86,441,231 |
1
PGIM Jennison International Opportunities Fund
Schedule of Investments as of July 31, 2020 (unaudited) (continued)
Description | Shares | Value | |||
Common Stocks (Continued) | |||||
Japan 3.2% | |||||
Freee KK* | 143,845 | $6,458,282 | |||
GMO Payment Gateway, Inc. | 261,225 | 27,242,337 | |||
Menicon Co. Ltd. | 499,154 | 24,241,687 | |||
57,942,306 | |||||
Netherlands 8.2% | |||||
Adyen NV, 144A* | 72,795 | 121,180,151 | |||
ASML Holding NV | 72,009 | 25,439,072 | |||
146,619,223 | |||||
Switzerland 6.8% | |||||
Alcon, Inc.* | 624,762 | 37,499,696 | |||
Givaudan SA | 13,520 | 56,019,083 | |||
Roche Holding AG | 78,749 | 27,395,043 | |||
120,913,822 | |||||
Taiwan 7.5% | |||||
Sea Ltd., ADR* | 666,052 | 81,391,554 | |||
Taiwan Semiconductor Manufacturing Co. Ltd., ADR | 672,994 | 53,092,497 | |||
134,484,051 | |||||
United Kingdom 6.0% | |||||
Abcam PLC | 1,384,600 | 23,277,132 | |||
AstraZeneca PLC | 329,034 | 36,463,610 | |||
Experian PLC | 1,370,122 | 48,068,584 | |||
107,809,326 | |||||
United States 7.5% | |||||
Atlassian Corp. PLC (Class A Stock)* | 267,698 | 47,288,852 | |||
Lululemon Athletica, Inc.*(a) | 201,667 | 65,660,758 | |||
Spotify Technology SA* | 81,073 | 20,902,241 | |||
133,851,851 | |||||
Total Common Stocks (cost $1,202,392,974) | 1,685,004,373 |
2
PGIM Jennison International Opportunities Fund
Schedule of Investments as of July 31, 2020 (unaudited) (continued)
Description | Shares | Value | |||
Preferred Stock 4.3% | |||||
Germany | |||||
Sartorius AG (PRFC) (cost $37,855,079) | 198,415 | $76,391,192 | |||
Total Long-Term Investments (cost $1,240,248,053) | 1,761,395,565 | ||||
Short-Term Investments 5.2% | |||||
Affiliated Mutual Funds | |||||
PGIM Core Ultra Short Bond Fund(w) | 40,526,267 | 40,526,267 | |||
PGIM Institutional Money Market Fund (cost $51,856,048; includes $51,793,621 of cash collateral for securities on loan)(b)(w) | 51,946,085 | 51,940,891 | |||
Total Short-Term Investments (cost $92,382,315) | 92,467,158 | ||||
TOTAL INVESTMENTS 103.6% (cost $1,332,630,368) | 1,853,862,723 | ||||
Liabilities in excess of other assets (3.6)% | (64,122,199) | ||||
Net Assets 100.0% | $1,789,740,524 |
Below is a list of the abbreviation(s) used in the quarterly schedule of portfolio holdings: |
144A—Security was purchased pursuant to Rule 144A under the Securities Act of 1933 and, pursuant to the requirements of Rule 144A, may not be resold except to qualified institutional buyers. | |
ADR—American Depositary Receipt | |
PRFC—Preference Shares |
* | Non-income producing security. |
(a) | All or a portion of security is on loan. The aggregate market value of such securities, including those sold and pending settlement, is $50,194,522; cash collateral of $51,793,621 (included in liabilities) was received with which the Series purchased highly liquid short-term investments. In the event of significant appreciation in value of securities on loan on the last business day of the reporting period, the Series may reflect a collateral value that is less than the market value of the loaned securities and such shortfall is remedied the following business day. |
(b) | Represents security, or portion thereof, purchased with cash collateral received for securities on loan and includes dividend reinvestment. |
(w) | PGIM Investments LLC, the manager of the Series, also serves as manager of the PGIM Core Ultra Short Bond Fund and PGIM Institutional Money Market Fund. |
Other information regarding the Series is available in the Series’ most recent Report to Shareholders. This information is available on the Securities and Exchange Commission’s website (www.sec.gov).
3